Dlugi A M, Laufer N, Decherney A H, Polan M L, Haseltine F P, Tarlatzis B C, Graebe R A, Barnea E R, Naftolin F
J In Vitro Fert Embryo Transf. 1985 Mar;2(1):33-40. doi: 10.1007/BF01130830.
The attainment of synchronous follicular development in human menopausal gonadotropin/human chorionic gonadotropin-stimulated cycles for in vitro fertilization (IVF) continues to be a perplexing problem. Two regimens of follicle stimulation for IVF cycles were, therefore, compared. Twenty-nine patients commenced human menopausal gonadotropin (hMG) therapy on day 1 of the menstrual cycle (Group I), while 30 women received hMG from the third day of the cycle (Group II). The hMG therapy was tailored to the individual patients's response, based on ultrasonographic measurements of follicular size and serum estradiol (E2) levels. Both groups of patients received a mean of 19.6 +/- 1.4 ampules of hMG over a mean of 6.1 +/- 0.2 days. The pattern of serum E2 and progesterone levels in the periovulatory and luteal phase was not affected by the day of initiation of hMG therapy, although Group I patients demonstrated lower (P less than 0.05) E2 levels on the 2 days prior to human chorionic gonadotropin (hCG) administration. In terms of follicle growth, Group II follicles consistently demonstrated a significantly (P less than 0.01, chi 2 test) larger proportion of medium- and large-sized follicles compared to Group I follicles on almost all of the days when ultrasonographic measurements were taken. In addition, Group II follicles demonstrated an earlier shift (day-1) to the larger follicles than Group I follicles (day 0). Significantly (P less than 0.001) more oocytes were recovered per aspirated follicle in Group II patients, but the fertilization rate per oocyte was greater (P less than 0.003) for Group I oocytes. Nevertheless, pregnancy rates did not differ between the two groups.(ABSTRACT TRUNCATED AT 250 WORDS)
在体外受精（IVF）中，实现人绝经期促性腺激素/人绒毛膜促性腺激素刺激周期的同步卵泡发育仍然是一个令人困惑的问题。因此，比较了两种IVF周期卵泡刺激方案。29例患者在月经周期第1天开始接受人绝经期促性腺激素（hMG）治疗（第一组），而30例女性在周期第3天接受hMG治疗（第二组）。根据卵泡大小的超声测量和血清雌二醇（E2）水平，hMG治疗方案根据个体患者的反应进行调整。两组患者在平均6.1±0.2天内平均接受了19.6±1.4安瓿的hMG。尽管第一组患者在注射人绒毛膜促性腺激素（hCG）前2天的E2水平较低（P<0.05），但hMG治疗开始日对围排卵期和黄体期血清E2和孕酮水平的模式没有影响。在卵泡生长方面，在几乎所有进行超声测量的日子里，与第一组卵泡相比，第二组卵泡始终显示出显著（P<0.01，卡方检验）更高比例的中型和大型卵泡。此外，第二组卵泡比第一组卵泡更早（第1天）向较大卵泡转变（第一组为第0天）。第二组患者每个抽吸卵泡回收的卵母细胞明显更多（P<0.001），但第一组卵母细胞的每个卵母细胞受精率更高（P<0.003）。然而，两组的妊娠率没有差异。（摘要截断于250字）
